Newsfiscal.ai
aTyr Pharma Announces Publication of Phase 3 EFZO-FIT™ Study Results for Efzofitimod
· Published
Article summary
aTyr Pharma, Inc. announced the publication of results from its Phase 3 EFZO-FIT™ study of efzofitimod for the treatment of pulmonary sarcoidosis in The Lancet Respiratory Medicine.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…